A debate is emerging regarding the designation of Grade Group 1 (GG1) prostate cancer, with concerns that grading may overlook vital diagnostic indicators, such as PSA levels. Research from Weill Cornell Medicine reveals that 1 in 6 men diagnosed with GG1 are later determined to have intermediate or high-risk disease, raising issues about patient understanding. Bashir Al Hussein emphasizes the need for better risk stratification combining histopathology, imaging, and clinical features to guide management decisions, ensuring patients receive accurate prognostic insights.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.